Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$2.38 +4.4%	$1.95	$0.80 ▼ $2.89	$562.23M	0.87	2.80 million shs	2.26 million shs
DNLI Denali Therapeutics	$15.68 +1.2%	$14.97	$10.57 ▼ $33.33	$2.28B	1.58	1.08 million shs	1.15 million shs
MIRM Mirum Pharmaceuticals	$40.80 +0.8%	$44.12	$23.83 ▼ $54.23	$2.02B	1	522,509 shs	186,097 shs
SDGR Schrödinger	$26.45 +1.2%	$22.14	$16.60 ▼ $28.47	$1.93B	1.77	836,416 shs	832,106 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	0.00%	+15.53%	+24.61%	+3.48%	+77.61%
DNLI Denali Therapeutics	0.00%	+23.08%	+6.09%	-32.38%	+1.62%
MIRM Mirum Pharmaceuticals	0.00%	+4.35%	-11.29%	-15.84%	+66.80%
SDGR Schrödinger	0.00%	+2.72%	+32.52%	+9.89%	+10.35%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKBA Akebia Therapeutics	3.5753 of 5 stars	3.5	1.0	4.0	2.7	0.8	0.6
DNLI Denali Therapeutics	4.0329 of 5 stars	4.5	0.0	4.7	2.9	1.7	0.0
MIRM Mirum Pharmaceuticals	4.2058 of 5 stars	3.5	1.0	4.2	3.5	3.3	0.6
SDGR Schrödinger	1.6844 of 5 stars	2.5	1.0	0.0	3.4	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKBA Akebia Therapeutics	3.00	Buy	$6.50	173.11% Upside
DNLI Denali Therapeutics	3.06	Buy	$37.57	139.61% Upside
MIRM Mirum Pharmaceuticals	3.09	Buy	$58.20	42.65% Upside
SDGR Schrödinger	3.00	Buy	$33.00	24.76% Upside

Current Analyst Ratings Breakdown

Latest AKBA, SDGR, DNLI, and MIRM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/24/2025	DNLI Denali Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/16/2025	SDGR Schrödinger	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$30.00 ➝ $32.00
4/10/2025	DNLI Denali Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
4/4/2025	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.50 ➝ $7.50
4/1/2025	AKBA Akebia Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00
3/14/2025	AKBA Akebia Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$4.00 ➝ $6.00
3/14/2025	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.50 ➝ $7.50
3/10/2025	DNLI Denali Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $28.00
3/7/2025	DNLI Denali Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$41.00 ➝ $33.00
3/5/2025	DNLI Denali Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $35.00
3/3/2025	DNLI Denali Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$50.00 ➝ $42.00

(Data available from 4/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKBA Akebia Therapeutics	$160.18M	3.51	N/A	N/A	($0.16) per share	-14.88
DNLI Denali Therapeutics	$330.53M	6.89	N/A	N/A	$7.42 per share	2.11
MIRM Mirum Pharmaceuticals	$336.89M	5.99	N/A	N/A	$5.33 per share	7.65
SDGR Schrödinger	$207.54M	9.31	$0.71 per share	37.42	$7.60 per share	3.48

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKBA Akebia Therapeutics	-$51.92M	-$0.33	N/A	N/A	N/A	-27.07%	N/A	-20.57%	5/8/2025 (Estimated)
DNLI Denali Therapeutics	-$145.22M	-$2.57	N/A	N/A	N/A	N/A	-32.94%	-30.04%	5/6/2025 (Estimated)
MIRM Mirum Pharmaceuticals	-$163.41M	-$1.85	N/A	N/A	N/A	-31.69%	-41.22%	-14.81%	5/6/2025 (Estimated)
SDGR Schrödinger	$40.72M	-$2.57	N/A	N/A	N/A	-91.84%	-35.77%	-24.51%	4/29/2025 (Estimated)

Latest AKBA, SDGR, DNLI, and MIRM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	MIRM Mirum Pharmaceuticals	-$0.35	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	AKBA Akebia Therapeutics	-$0.03	N/A	N/A	N/A	$44.88 million	N/A
5/7/2025	Q1 2025	SDGR Schrödinger	-$0.81	N/A	N/A	N/A	$54.60 million	N/A
5/6/2025	Q1 2025	DNLI Denali Therapeutics	-$0.73	N/A	N/A	N/A	$3.24 million	N/A
3/13/2025	Q4 2024	AKBA Akebia Therapeutics	-$0.05	-$0.10	-$0.05	-$0.10	$37.36 million	$46.50 million
2/27/2025	Q4 2024	DNLI Denali Therapeutics	-$0.75	-$0.67	+$0.08	-$0.67	$12.75 million	N/A
2/26/2025	Q4 2024	MIRM Mirum Pharmaceuticals	-$0.27	-$0.49	-$0.22	-$0.49	$96.64 million	$99.41 million
2/26/2025	Q4 2024	SDGR Schrödinger	-$0.35	-$0.55	-$0.20	-$0.55	$83.20 million	$88.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SDGR Schrödinger	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKBA Akebia Therapeutics	N/A	1.52	1.21
DNLI Denali Therapeutics	N/A	9.98	9.98
MIRM Mirum Pharmaceuticals	1.33	3.34	3.15
SDGR Schrödinger	N/A	4.11	4.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKBA Akebia Therapeutics	33.92%
DNLI Denali Therapeutics	92.92%
MIRM Mirum Pharmaceuticals	N/A
SDGR Schrödinger	79.05%

Insider Ownership

Company	Insider Ownership
AKBA Akebia Therapeutics	4.10%
DNLI Denali Therapeutics	7.90%
MIRM Mirum Pharmaceuticals	22.87%
SDGR Schrödinger	8.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKBA Akebia Therapeutics	430	236.23 million	209.24 million	Optionable
DNLI Denali Therapeutics	430	145.24 million	132.55 million	Optionable
MIRM Mirum Pharmaceuticals	140	49.45 million	37.03 million	Optionable
SDGR Schrödinger	790	73.04 million	66.59 million	Optionable

AKBA, SDGR, DNLI, and MIRM Headlines

Recent News About These Companies

Schrödinger, Inc. (NASDAQ:SDGR) Shares Bought by Envestnet Asset Management Inc.

April 27 at 3:16 AM | marketbeat.com

Natixis Takes Position in Schrödinger, Inc. (NASDAQ:SDGR)

April 25 at 5:02 AM | marketbeat.com

Schrödinger, Inc. (SDGR): Among Top Stocks in Bill Gates’ Portfolio with Huge Upside Potential

April 24, 2025 | finance.yahoo.com

Schrödinger, Inc. (NASDAQ:SDGR) Receives $33.00 Consensus PT from Brokerages

April 24, 2025 | americanbankingnews.com

Schrödinger, Inc. (SDGR): Among Top Stocks in Bill Gates’ Portfolio with Huge Upside Potential

April 23, 2025 | msn.com

Schrödinger to Announce First Quarter 2025 Financial Results on May 7

April 23, 2025 | finance.yahoo.com

LPL Financial LLC Has $797,000 Stock Holdings in Schrödinger, Inc. (NASDAQ:SDGR)

April 23, 2025 | marketbeat.com

Schrödinger, Inc. (NASDAQ:SDGR) Given Average Rating of "Buy" by Brokerages

April 22, 2025 | marketbeat.com

3 Momentum Stocks That Could Soar Post-Market Volatility (SDGR)

April 21, 2025 | marketbeat.com

Schrödinger, Inc. (NASDAQ:SDGR) Position Reduced by Russell Investments Group Ltd.

April 21, 2025 | marketbeat.com

KeyCorp Forecasts Strong Price Appreciation for Schrödinger (NASDAQ:SDGR) Stock

April 18, 2025 | marketbeat.com

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

April 18, 2025 | businesswire.com

Schrödinger, Inc. (NASDAQ:SDGR) Insider Sells $419,580.07 in Stock

April 17, 2025 | marketbeat.com

Schrödinger (NASDAQ:SDGR) Trading Down 2.4% - Here's What Happened

April 17, 2025 | marketbeat.com

An Intrinsic Calculation For Schrödinger, Inc. (NASDAQ:SDGR) Suggests It's 26% Undervalued

April 17, 2025 | uk.finance.yahoo.com

Schrödinger (NASDAQ:SDGR) Trading Up 8.1% - What's Next?

April 16, 2025 | marketbeat.com

Schrödinger, Inc. (NASDAQ:SDGR) Insider Karen Akinsanya Sells 16,723 Shares

April 16, 2025 | insidertrades.com

Karen Akinsanya von Schrodinger verkauft Aktien im Wert von 419.570 US-Dollar

April 15, 2025 | de.investing.com

Schrodinger issues statement on FDA phasing out animal testing requirement

April 15, 2025 | markets.businessinsider.com

ExodusPoint Capital Management LP Takes Position in Schrödinger, Inc. (NASDAQ:SDGR)

April 15, 2025 | marketbeat.com

Schrödinger unterstützt FDA-Initiative zur Reduzierung von Tierversuchen

April 14, 2025 | de.investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKBA, SDGR, DNLI, and MIRM Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

$2.38 +0.10 (+4.39%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$2.38 0.00 (-0.21%)

As of 04/25/2025 07:43 PM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Denali Therapeutics NASDAQ:DNLI

$15.68 +0.19 (+1.23%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$15.69 +0.01 (+0.06%)

As of 04/25/2025 07:45 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Mirum Pharmaceuticals NASDAQ:MIRM

$40.80 +0.33 (+0.82%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$43.15 +2.35 (+5.76%)

As of 04/25/2025 04:55 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Schrödinger NASDAQ:SDGR

$26.45 +0.32 (+1.22%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$26.05 -0.40 (-1.51%)

As of 04/25/2025 07:08 PM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time